AZN - AstraZeneca Tries To Reach New Ground For Its Lead Cancer Drug Imfinzi With New Data In Liver Cancer Study | Benzinga

AstraZeneca Plc (NASDAQ:AZN) released results from the EMERALD-1 Phase 3 trial of Imfinzi plus TACE concurrently, followed by Imfinzi with or without bevacizumab until progression versus transarterial chemoembolization (TACE) alone in 616 patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization.

The data showed that Imfinzi (durvalumab), combined with TACE and bevacizumab, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to TACE.

Also Read: Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned.

These results will be presented ...

Full story available on Benzinga.com